Skip to main content
SpringerLink
Log in

Neuroblastoma: solving a biologic puzzle

  • Chapter
Diagnostic and Therapeutic Advances in Pediatric Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 92))

Abstract

Neuroblastoma, a childhood tumor arising in the adrenal medulla and sympathetic nervous system, presents an unusual challenge to pediatric oncologists. While virtually all patients with localized neuroblastoma can be cured by surgery alone, and most infants with disseminated disease are curable with chemotherapy, children with bone metastases usually have a fatal outcome [1–4]. Furthermore, in some patients the tumor undergoes spontaneous regression or differentiation [5,6]. This wide range of clinical behavior reflects the biologic heterogeneity of neuroblastoma. Much progress has been made recently in advancing our knowledge of human neuroblastoma at the cellular and molecular level, and specific genetic abnormalities have been identified that are characteristic of subsets of these tumors [7]. These transformation-linked genetic changes have contributed to our understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. Continued study of these genetic abnormalities will hopefully lead to further insight into the molecular events associated with the malignant transformation of this heterogeneous tumor, and thereby provide clues for the development of specific therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nitschke R, Smith EI, Shochat S, et al. 1988. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol 6:1271–1279.

    PubMed  CAS  Google Scholar 

  2. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. 1989. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 7:236–244.

    PubMed  CAS  Google Scholar 

  3. Look AT, Hayes FA, Shuster JJ, et al. 1991. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581–591.

    PubMed  CAS  Google Scholar 

  4. Evans AE, D’Angio GJ, Randolph J. 1971. A proposed staging for children with neuroblastoma. Children’s Cancer Study Group A. Cancer 27:374–378.

    PubMed  CAS  Google Scholar 

  5. Evans AE, Gerson J, Schnaufer L. 1976. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 44:49–54.

    PubMed  CAS  Google Scholar 

  6. D’Angio GJ, Evans AE, Koop CE. 1971. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1:1046–1049.

    PubMed  Google Scholar 

  7. Brodeur GM, Azar C, Brother M, et al. 1992. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 70:1685–1694.

    PubMed  CAS  Google Scholar 

  8. Young JL, Jr., Miller RW. 1975. Incidence of malignant tumors in U.S. children. J Pediatr 86:254–258.

    PubMed  Google Scholar 

  9. Perkins DG, Koop CM, Haust MD. 1980. Placental infiltration in congenital neuroblastoma. Histopathology 4:383.

    PubMed  CAS  Google Scholar 

  10. Lopez R, Karakousis C, Rad U. 1980. Treatment of adult neuroblastoma. Cancer 45:840.

    PubMed  CAS  Google Scholar 

  11. Bunin GR, Ward E, Kramer S. Rhee CA, Meadows AT. 1990. Neuroblastoma and parental occupation. Am J Epidemiol 131:776–780.

    PubMed  CAS  Google Scholar 

  12. Kramer S, Ward E, Meadows AT, Malone KE. 1987. Medical and drug risk factors associated with neuroblastoma: a case-control study. J Natl Cancer Inst 78:797–804.

    PubMed  CAS  Google Scholar 

  13. Kinney H, Faix R, Brazy J. 1980. The fetal alcohol syndrome and neuroblastoma. Pediatrics 66:130–132.

    PubMed  Google Scholar 

  14. Kushner BH, Hajdu SI, Helson L. 1985. Synchronous neuroblastoma and von Recklinghausen’s disease: a review of the literature. J Clin Oncol 3:117–120.

    PubMed  CAS  Google Scholar 

  15. Carachi R, Auldist AW, Chow CW. 1982. Neuroblastoma and Hirschsprung’s disease. Z Kinderchir 35:24–25.

    PubMed  CAS  Google Scholar 

  16. Kushner BH, Gilbert F, Helson L. 1986. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 57:1887–1893.

    PubMed  CAS  Google Scholar 

  17. Laureys G, Speleman F, Opdenakker G, Benoit Y, Leroy J. 1990. Constitutional translocation t(1;17)(p36;ql2–21) in a patient with neuroblastoma. Genes Chromosomes Cancer 2:252–254.

    PubMed  CAS  Google Scholar 

  18. Biegel JA, White PS, Marshall HN, et al. 1993. Constitutional lp36 deletion in a child with neuroblastoma. Am J Hum Genet 52:176–182.

    PubMed  CAS  Google Scholar 

  19. Bronner-Fraser M. 1995. Origins and developmental potential of the neural crest. Exp Cell Biol 218:405–417.

    CAS  Google Scholar 

  20. Landau M. 1912. Die maligne neuroblastoma des sympathicus, frank. Z Pathol 11:26.

    Google Scholar 

  21. Ambros IM, Zellner A, Roald B, et al. 1996. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 334:1505–1511.

    PubMed  CAS  Google Scholar 

  22. Lopez-Ibor B, Schwartz AD. 1985. Neuroblastoma. Pediatr Clin North Am 32:755–778.

    PubMed  CAS  Google Scholar 

  23. Voute PA. 1984. Neuroblastoma. In Sutow WW, Fernbach DJ, Vietti TJ (eds.). Clinical Pediatric Oncology. St. Louis: The C.V. Mosby Company, pp. 559–587.

    Google Scholar 

  24. Gonzalez-Crussi F, Hsueh W. 1988. Bilateral adrenal ganglioneuroblastoma with neuro-melanin. Clinical and pathologic observations. Cancer 61:1159–1166.

    CAS  Google Scholar 

  25. Broducr GM, Castelberry RP. 1993. Neuroblastoma. In Pizzo PA, Poplack DG (eds.). Principles and Practice of Pediatric Oncology. J.B. Lippincott Co., pp. 739–767.

    Google Scholar 

  26. Hayes FA, Thompson EI, Hvizdala E, O’Connor D, Green AA. 1984. Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. J Pediatr 104:221–224.

    PubMed  CAS  Google Scholar 

  27. van der Slikke JW, Balk AG. 1980. Hydramnios and hydrops fetalis and disseminated fetal neuroblastoma. Obstet Gynecol 55:250.

    PubMed  Google Scholar 

  28. Weinblatt ME, Heisel MA, Siegel SE. 1983. Hypertension in children with neurogenic tumors. Pediatrics 71:947–951.

    CAS  Google Scholar 

  29. Mitchell CH, Sinatra FR, Crast FW, Griffin R, Sunshine P. 1976. Intractable watery diarrhea, ganglioneuroblastoma, and vasoactive intestinal peptide. J Pediatr 89:593–595.

    PubMed  CAS  Google Scholar 

  30. Mendelsohn G, Eggleston JC, Olson JL, Said SI, Baylin SB. 1979. Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. Lab Invest 41:144–149.

    PubMed  CAS  Google Scholar 

  31. Altman AJ, Baehner RL. 1976. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 37:846–852.

    PubMed  CAS  Google Scholar 

  32. Cohn SL, Salwen H, Herst CV, et al. 1988. Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. Cancer 62:723–726.

    PubMed  CAS  Google Scholar 

  33. Kofi PS, Raffensperger JG, Berry S, et al. 1994. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 125:712–716.

    Google Scholar 

  34. Nickerson BG, Hutter JJ. 1979. Opsoclonus and neuroblastoma: response to ACTH. Clin Pediatr 18:446–448.

    CAS  Google Scholar 

  35. Petruzzi MI, de Alarcon PA. 1995. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 127:328–329.

    PubMed  CAS  Google Scholar 

  36. Telander RL, Smithson WA, Groover RV. 1989. Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg 24:11–14.

    PubMed  CAS  Google Scholar 

  37. Mitchell WG, Snodgrass SR. 1990. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 5:153–158.

    PubMed  CAS  Google Scholar 

  38. Pranzatelli MR. 1992. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 15:186–228.

    PubMed  CAS  Google Scholar 

  39. Ziter FA, Brav PF, Cancilla PA. 1979. Neuropathologic findings in a patient with neuroblastoma and myoclonic encephalopathy. Arch Neurol 36:51.

    PubMed  CAS  Google Scholar 

  40. Donner L, Triche TJ, Israel MA, Seeger RC, Reynolds CP. 1985. A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing’s sarcoma, rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies. Prog Clin Biol Res 175:347–366.

    PubMed  CAS  Google Scholar 

  41. Israel MA, Thiele C, Whang-Peng J, Kao-Shan CS, Triche TJ, Miser J. 1985. Peripheral neuroepithelioma: genetic analysis of tumor derived cell lines. Prog Clin Biol Res 175:161–170.

    PubMed  CAS  Google Scholar 

  42. Triche TJ, Askin FB. 1983. Neuroblastoma and the differential diagnosis of small-, round-, blue-cell tumors. Hum Pathol 14:569–595.

    PubMed  CAS  Google Scholar 

  43. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA. 1984. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 311:584–585.

    PubMed  CAS  Google Scholar 

  44. Triche TJ. 1982. Round cell tumors in childhood: the application of newer techniques to the differential diagnosis. Persp Pediatr Pathol 7:279–322.

    CAS  Google Scholar 

  45. Biegel JA, Nycum LM, Valentine V, Barr FG, Shapiro DN. 1995. Detection of the t(2;13)(q35;ql4) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. Genes Chromosomes Cancer 12:186–192.

    PubMed  CAS  Google Scholar 

  46. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. 1993. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53:5108–5112.

    PubMed  CAS  Google Scholar 

  47. Douglass EC, Shapiro DN, Valentine M, et al. 1993. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 21:83–87.

    PubMed  Google Scholar 

  48. Brodeur GM, Pritchard J, Berthold F, et al. 1993. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477.

    PubMed  CAS  Google Scholar 

  49. Bertani-Dziedzic L, Dziedzic SW, Gitlow SE. 1990. Catecholamine metabolism in neuroblastoma. In Pochedly C (ed.). Neuroblastoma: Tumor Biology and Therapy. Boca Raton: CRC, pp. 69–91.

    Google Scholar 

  50. Evans AE, D’Angio GJ, Propert K, Anderson J, Hann HL. 1987. Prognostic factors in neuroblastoma. Cancer 59:1853–1859.

    PubMed  CAS  Google Scholar 

  51. Heisel MA, Miller JH, Reid BS, Siegel SE. 1983. Radionuclide bone scan in neuroblastoma. Pediatrics 71:206–209.

    PubMed  CAS  Google Scholar 

  52. Gordon I, Peters AM, Guiman A, Morony S, Dicks-Mireaux C, Pritchard J. 1990. Skeletal assessment in neuroblastoma—the pitfalls of iodine-123-MIBG scans. J Nucl Med 31:129–134.

    PubMed  Google Scholar 

  53. Smith EI, Castelberry RP. 1990. Neuroblastoma. Curr Prob Surg 27:573–620.

    CAS  Google Scholar 

  54. Hayes FA, Green A, Hustu HO, Kumar M, 1983. Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. J Pediatr 102:59–62.

    PubMed  CAS  Google Scholar 

  55. American Joint Committee on Cancer. 1983. Neuroblastoma. Manual for Staging of Cancer. Philadelphia: J.B. Lippincott, p. 237.

    Google Scholar 

  56. Brodeur GM, Seeger RC, Barrett A, et al. 1988. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874–1881.

    PubMed  CAS  Google Scholar 

  57. Castleberry RP, Shuster JJ, Smith EI, Member institutions of Pediatric Oncology Group. 1994. The Pediatric Oncology Group experience with the International Staging System criteria for neuroblastoma. J Clin Oncol 12:2378–2381.

    PubMed  Google Scholar 

  58. Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. 1995. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 30:289–294.

    PubMed  CAS  Google Scholar 

  59. Breslow N, McCann B. 1971. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31:2098–2103.

    PubMed  CAS  Google Scholar 

  60. Seeger RC, Brodeur GM, Sather H, et al. 1985. Association of multiple copies of the N-myc oncogene with repid progression of neuroblastomas. N Engl J Med 313:1111–1116.

    PubMed  CAS  Google Scholar 

  61. Philip T. 1992. Overview of current treatment of neuroblastoma. Am J Pediatr Hematol Oncol 14:97–102.

    PubMed  CAS  Google Scholar 

  62. Finklestein JZ, Klemperer MR, Evans A, et al. 1979. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Med Pediatr Oncol 6:179–188.

    PubMed  CAS  Google Scholar 

  63. Hann HW, Levy HM, Evans AE. 1980. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 40:1411–1413.

    PubMed  CAS  Google Scholar 

  64. Quinn JJ, Altman AJ, Frantz CN. 1980. Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 97:89–91.

    PubMed  CAS  Google Scholar 

  65. Zeltzer PM, Marangos PJ, Parma AM, et al. 1983. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children’s Cancer Study Group. Lancet 2:361–363.

    PubMed  CAS  Google Scholar 

  66. Zeltzer PM, Marangos PJ, Sather H, et al. 1985. Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. Prog Clin Biol Res 175:319–329.

    PubMed  CAS  Google Scholar 

  67. Shimada H, Chatten J, Newton WA Jr, et al. 1984. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405–416.

    PubMed  CAS  Google Scholar 

  68. Joshi VV, Cantor AB, Altshuler G, et al. 1992. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group. Cancer 69:2183–2196.

    PubMed  CAS  Google Scholar 

  69. Joshi VV, Cantor AB, Altshuler G, et al. 1992. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer 69:2197–2211.

    PubMed  CAS  Google Scholar 

  70. Shimada H, Stram DO, Chatten J, et al. 1995. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470–1476.

    PubMed  CAS  Google Scholar 

  71. Cohn SL, Rademaker AW, Salwen HR, et al. 1990. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 136:1043–1052.

    PubMed  CAS  Google Scholar 

  72. Brodeur GM, Fong CT. 1989. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41:153–174.

    PubMed  CAS  Google Scholar 

  73. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. 1981. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41:4678–4686.

    PubMed  CAS  Google Scholar 

  74. Schwab M, Alitalo K, Klempnauer KH, et al. 1983. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305:245–248.

    PubMed  CAS  Google Scholar 

  75. Human gene mapping. London Conference, 1991. Eleventh International Workshop on Human Gene Mapping. Cytogenet Cell Genet 58:1–984.

    Google Scholar 

  76. Schwab M, Varmus HE, Bishop JM, et al. 1984. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308:288–291.

    PubMed  CAS  Google Scholar 

  77. Kohl NE, Kanda N, Schreck RR, et al. 1983. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35:359–367.

    PubMed  CAS  Google Scholar 

  78. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. 1984. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124.

    PubMed  CAS  Google Scholar 

  79. Brodeur GM, Hayes FA, Green AA, et al. 1987. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 47:4248–4253.

    PubMed  CAS  Google Scholar 

  80. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. 1990. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 50:4411–4416.

    PubMed  CAS  Google Scholar 

  81. Bernards R, Dessain SK, Weinberg RA. 1986. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47:667–674.

    PubMed  CAS  Google Scholar 

  82. Schmidt ML, Salwen HR, Manohar CF, Ikegaki N, Cohn SL. 1994. The biologic effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ 5:171–178.

    PubMed  CAS  Google Scholar 

  83. Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A, Raschella G. 1991. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 2:511–518.

    PubMed  CAS  Google Scholar 

  84. Whitesell L, Rosolen A, Neckers LM. 1991. Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines. Mol Cell Biol 11:1360–1371.

    PubMed  CAS  Google Scholar 

  85. Thiele CJ, Reynolds CP, Israel MA. 1985. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404–406.

    PubMed  CAS  Google Scholar 

  86. Thiele CJ, Israel MA. 1988. Regulation of N-myc expression is a critical event controlling the ability of human neuroblasts to differentiate. Exp Cell Biol 56:321–333.

    PubMed  CAS  Google Scholar 

  87. Ikegaki N, Bukovsky J, Kennett RH. 1986. Identification and characterization of the N-myc gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. Proc Natl Acad Sci USA 83:5929–5933.

    PubMed  CAS  Google Scholar 

  88. Blackwood EM, Eisenman RN. 1991. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211–1217.

    PubMed  CAS  Google Scholar 

  89. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. 1990. Sequence-specific DNA binding by the c-Myc protein. Science 250:1149–1151.

    PubMed  CAS  Google Scholar 

  90. Schneider SS, Hiemstra JL, Zehnbauer BA, et al. 1992. Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. Mol Cell Biol 12:5563–5570.

    PubMed  CAS  Google Scholar 

  91. Manohar CF, Salwen HR, Brodeur GM, Cohn SL. 1995. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Genes Chromosomes Cancer 14:196–203.

    PubMed  CAS  Google Scholar 

  92. Squire JA, Thorner PS, Weitzman S, et al. 1995. Co-amplification of MYCN and a DEAD box gene (DDXI) in primary neuroblastoma. Oncogene 10:1417–1422.

    PubMed  CAS  Google Scholar 

  93. George RE, Kenyon RM, McGuckin AG, et al. 1996. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. Oncogene 12:1583–1587.

    PubMed  CAS  Google Scholar 

  94. Schmid SR, Under P. 1992. D-E-A-D protein family of putative RNA helicases. Mol Microbiol 6(3):283–291.

    Google Scholar 

  95. Cohn SL, Look AT, Joshi VV, et al. 1995. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group Study. Cancer Res 55:721–726.

    PubMed  Google Scholar 

  96. Fabbretti G, Valenti C, Loda M, et al. 1993. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol 24:294–297.

    PubMed  CAS  Google Scholar 

  97. Nisen PD, Waber PG, Rich MA, et al. 1988. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 80:1633–1637.

    PubMed  CAS  Google Scholar 

  98. Slavc I, Ellenbogen R, Jung WH, et al. 1990. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 50:1459–1463.

    PubMed  Google Scholar 

  99. Grady-Leopardi EF, Schwab M, Ablin AR, Rosenau W, 1986. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome. Cancer Res 46:3196–3199.

    PubMed  CAS  Google Scholar 

  100. Shapiro DN, Valentine MB, Rowe ST, et al. 1993. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 142:1339–1346.

    PubMed  CAS  Google Scholar 

  101. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. 1984. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231–235.

    PubMed  Google Scholar 

  102. Taylor SR, Locker J. 1990. A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer 65:1360–1366.

    PubMed  CAS  Google Scholar 

  103. Oppedal BR, Storm-Mathisen I, Lie SO, Brandtzaeg P. 1988. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer 62:722–780.

    Google Scholar 

  104. Taylor SR, Blatt J, Costantino JP, Roederer M, Murphy RF. 1988. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer 62:749–754.

    PubMed  CAS  Google Scholar 

  105. Gansler T, Chatten J, Varello M, Bunin GR, Atkinson B. 1986. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer 58:2453–2458.

    PubMed  CAS  Google Scholar 

  106. Bourhis J, DeVathaire F, Wilson GD, et al. 1991. Combined analysis of DNA ploidy index and N-myc genomic content in enuroblastoma. Cancer Res 51:33–36.

    PubMed  CAS  Google Scholar 

  107. Oppedal BR, Oien O, Jahnsen T, Brandtzaeg P. 1989. N-myc amplification in neuoblastomas: histopathological, NDA ploidy, and clinical variables. J Clin Pathol 42:1148–1152.

    PubMed  CAS  Google Scholar 

  108. Kaneko Y, Kanda N, Maseki N, et al. 1987. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47:311–318.

    PubMed  CAS  Google Scholar 

  109. Fong CT, Dracopoli NC, White PS, et al. 1989. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 86:3753–3757.

    PubMed  CAS  Google Scholar 

  110. Weith A, Martinsson T, Cziepluch C, et al. 1989. Neuroblastoma Consensus deletion maps to 1p36.l–2. Genes Chromosomes Cancer 1:159–166.

    PubMed  CAS  Google Scholar 

  111. Takeda O, Homma C, Maseki N, et al. 1994. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 10:30–39.

    PubMed  CAS  Google Scholar 

  112. Schleiermacher G, Peter M, Michon J, et al. 1994. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 10:275–281.

    PubMed  CAS  Google Scholar 

  113. White PS, Maris JM, Beltinger C, et al. 1995. A region of consistent deletion in neuroblastoma maps within human chromosome 1 p36.2–36.3 Proc Natl Acad Sci USA 92:5520–5524.

    PubMed  CAS  Google Scholar 

  114. Maris JM, White PS, Beltinger CP, et al. 1995. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55:4664–4669.

    PubMed  CAS  Google Scholar 

  115. Gehring M, Berthold F, Edler L, Schwab M, Amler LC. 1995. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 55:5366–5369.

    PubMed  CAS  Google Scholar 

  116. Caron H, van Sluis P, de Kraker J, et al. 1996. Allelic toss of chromosome lp as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225–230.

    PubMed  CAS  Google Scholar 

  117. Thoenen H, Barde YA. 1980. Physiology of nerve growth factor. Physiol Rev 60:1284–1335.

    PubMed  CAS  Google Scholar 

  118. Chen J, Chattopadhyay B, Venkatakrishnan G, Ross AH. 1990. Nerve growth factor-induced differentiation of human neuroblastoma and neuroepithelioma celli lines. Cell Growth Differ 1:79–85.

    PubMed  CAS  Google Scholar 

  119. Azar CG, Scavarda NJ, Reynolds CP, Brodeur GM. 1990. Multiple defects of the nerve growth factor receptor in human neuroblastomas. Cell Growth Differ 1:421–428.

    PubMed  CAS  Google Scholar 

  120. Green SH, Greene LA. 1986. A single Mr approximately 103,000 125I-beta-nerve growth factor- affinity-labeled species represents both the low and high affinity forms of the nerve growth factor receptor. J Biol Chem 261:15316–15326.

    PubMed  CAS  Google Scholar 

  121. Martin-Zanca D, Barbacid M, Parada LF. 1990. Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev 4:683–694.

    PubMed  CAS  Google Scholar 

  122. Kaplan DR, Martin-Zanca D, Parada LF. 1991. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350:158–160.

    PubMed  CAS  Google Scholar 

  123. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. 1993. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847–854.

    PubMed  CAS  Google Scholar 

  124. Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlman S. 1995. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Differ 6:727–736.

    PubMed  CAS  Google Scholar 

  125. Matsushima H, Bogenmann E. 1993. Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro an in vivo. Mol Cell Biol 13:7447–7456.

    PubMed  CAS  Google Scholar 

  126. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. 1993. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53:2044–2050.

    PubMed  CAS  Google Scholar 

  127. Borrello MG, Bongarzone I, Pierotti MA, et al. 1993. TRK and RET protooncogene expression in human neuroblastoma specimens: high-frequency of TRK expression in nonadvanced stages. Int J Cancer 54:540–545.

    PubMed  CAS  Google Scholar 

  128. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. 1993. Lack of high-affinily nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85:337–384.

    Google Scholar 

  129. 1991. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Editor Roninson, IB, Plenum Press.

    Google Scholar 

  130. Chan HSL, Haddad G, Thorner PS, et al. 1991. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614.

    PubMed  CAS  Google Scholar 

  131. Favrot M, Combaret V, Goillot E, et al. 1991. Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 64:233–238.

    PubMed  CAS  Google Scholar 

  132. Nakagawara A, Kadomatsu K, Sato S, et al. 1990. Inverse conrrelation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 50:3043–3047.

    PubMed  CAS  Google Scholar 

  133. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. 1996. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231–238.

    PubMed  CAS  Google Scholar 

  134. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. 1994. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357–361.

    PubMed  CAS  Google Scholar 

  135. Cole SP, Bhardwaj G, Gerlach JH, et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654.

    PubMed  CAS  Google Scholar 

  136. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP. 1993. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53:3221–3225.

    PubMed  CAS  Google Scholar 

  137. Zaman GJ, Flens MJ, van Leusden MR, et al. 1994. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 91:8822–8826.

    PubMed  CAS  Google Scholar 

  138. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. 1994. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene I childhood neuroblastoma. Cancer Res 54:5036–5040.

    PubMed  CAS  Google Scholar 

  139. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6.

    PubMed  CAS  Google Scholar 

  140. Folkman J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27–31.

    PubMed  CAS  Google Scholar 

  141. Weinstat-Saslow D, Steeg PS, 1994. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8:401–407.

    PubMed  CAS  Google Scholar 

  142. Weidner N, Folkman J, Pozza F, et al. 1992. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887.

    PubMed  CAS  Google Scholar 

  143. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. 1993. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409.

    PubMed  CAS  Google Scholar 

  144. Toi M, Kashitani J, Tominaga T. 1993. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371–374.

    PubMed  CAS  Google Scholar 

  145. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. 1992. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340:145–146.

    PubMed  CAS  Google Scholar 

  146. Maeda K, Chung Y, Takatsuka S, et al. 1995. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13:477–481.

    PubMed  CAS  Google Scholar 

  147. Meitar D, Crawford SE, Rademaker AW, Cohn SL. 1996. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:405–414.

    PubMed  CAS  Google Scholar 

  148. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. 1990. CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313.

    PubMed  CAS  Google Scholar 

  149. Jalkanen ST, Bargatze RF, Herron LR, Butcher EC. 1986. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 15:1195–1202.

    Google Scholar 

  150. Miyake K, Underhill CB, Lesley J, Kincade PW. 1990. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J EXT Med 172:69–75.

    CAS  Google Scholar 

  151. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. 1989. CD44 contributes to T cell activation. J Immunol 143:798–801.

    PubMed  CAS  Google Scholar 

  152. St. John T, Meyer J, Idzerda R, Gallatin WM. 1990. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 60:45–52.

    PubMed  Google Scholar 

  153. Jalkanen S, Joensuu H, Soderstrom KO, Klemi P. 1991. Lymphocyte homing and clinical behavior of non-Hodgkin’s lymphoma. J Clin Invest 87:1835–1840.

    PubMed  CAS  Google Scholar 

  154. Matsumura Y, Tarin D. 1992. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340:1053–1058.

    PubMed  CAS  Google Scholar 

  155. Favrot MC, Combaret V, Lasset C. 1993. CD44 — a new prognostic marker for neuroblastoma. N Engl J Med 329:1965.

    PubMed  CAS  Google Scholar 

  156. Combaret V, Gross N, Lasset C, et al. 1996. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14:25–34.

    PubMed  CAS  Google Scholar 

  157. Combaret V, Lasset C, Frappaz D, et al. 1995. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 31A:545–549.

    PubMed  CAS  Google Scholar 

  158. Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D, Beck D. 1994. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 54:4238–4242.

    PubMed  CAS  Google Scholar 

  159. Kodama K, Nakata T, Ishii J, et al. 1985. VMA mass screening program of neuroblastoma for infants in Nagoya City, Japan. Am J Public Health 75:173–175.

    PubMed  CAS  Google Scholar 

  160. Sawada T, Kidowaki T, Sakamoto I, et al. 1984. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 53:2731–2735.

    PubMed  CAS  Google Scholar 

  161. Nishi M, Miyake H, Takeda T, et al. 1992. Mass screening of neuroblastoma in Sapporo City, Japan. Am J Pediatr Hematol Oncol 14:327–331.

    PubMed  CAS  Google Scholar 

  162. Yamamoto K, Hayashi Y, Hanada R. et al. 1995. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 13:2033–2038.

    PubMed  CAS  Google Scholar 

  163. Ishimoto K, Kiyokawa N, Fujita H, et al. 1990. Problems of mass screening for neuroblastoma: analysis of false-negative cases. J Pediatr Surg 25:398–401.

    PubMed  Google Scholar 

  164. Nakagawara A, Zaizen Y, Ikeda K, et al. 1991. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 68:2037–2044.

    PubMed  CAS  Google Scholar 

  165. Kaneko Y, Kanda N, Maseki N, et al. 1990. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 8:2005–2013.

    PubMed  CAS  Google Scholar 

  166. Bessho F, Hashizume K, Nakajo T, Kamoshita S. 1991. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 119:237–241.

    PubMed  CAS  Google Scholar 

  167. Craft AW, Parker L, Dale G, et al. 1992. A pilot study of screening for neuroblastoma in the north of England. Am J Pediatr Hematol Oncol 14:337–341.

    PubMed  CAS  Google Scholar 

  168. Woods WG, Tuchman M, Bernstein ML, et al. 1992. Screening for neuroblastoma in North America. 2-year results from the Quebec Project. Am J Pediatr Hematol Oncol 14:312–319.

    PubMed  CAS  Google Scholar 

  169. Schilling FH, Erttmann R, Dohrmann S, et al. 1992. Early neuroblastoma detection in Germany. On the status of the Hamburg-Stuttgart cooperative pilot study. Klin Padiatr 204:282–287.

    PubMed  CAS  Google Scholar 

  170. Treuner J, Schilling FH. 1995. Neuroblastoma mass screening: the arguments for and against. Eur J Cancer 31A:565–568.

    PubMed  CAS  Google Scholar 

  171. Takeuchi LA, Hachitanda Y, Woods WG, et al. 1995. Screening for neuroblastoma in North America: preliminary results of a pathology review from the Quebec project. Cancer 76:2363–2371.

    PubMed  CAS  Google Scholar 

  172. Murphy SB, Cohn SL, Craft. AW, et al. 1991. Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening. Lancet 337:344–346.

    PubMed  CAS  Google Scholar 

  173. Esteve J. 1994. Some remarks on power calculation for neuroblastoma screening. In Sawada T, Matsumura T, Kizaki Z (eds.). Proceedings of the 3rd International Symposium on Neuroblastoma Screening. Kyoto: Kyoto Prefectural Unviersity of Medicine, pp. 47–51.

    Google Scholar 

  174. Evans AE, Albo V, D’Angio GJ, et al. 1976. Factors influencing survival of children with nonmetastatic neuroblastoma. Cancer 38:661–666.

    PubMed  CAS  Google Scholar 

  175. De Bernardi B, Conte M, Mancini A, et al. 1995. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 13:884–893.

    PubMed  Google Scholar 

  176. Ninane J, Pritchard J, Morris Jones PH, Mann JR, Malpas JS. 1982. Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement. Arch Dis Child 57:438–442.

    PubMed  CAS  Google Scholar 

  177. Kushner BH, Cheung NV, LaQuaglia MP, et al. 1996. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 14:373–381.

    PubMed  CAS  Google Scholar 

  178. Evans AE, Baum E, Chard R. 1981. Do infants with stage IV-S neuroblastoma need treatment? Arch Dis Child 56:271–274.

    PubMed  CAS  Google Scholar 

  179. Cohn SL, Herst CV, Maurer HS, Rosen ST. 1987. N-myc amplification in an infant with stage IVS neuroblastoma. J Clin Oncol 5:1441–1444.

    PubMed  CAS  Google Scholar 

  180. Bowman L, Castleberry R, Altshuler G, et al. 1992. Therapy based on DNA index (DI) for infants with unresectable and disseminated neuroblastoma (NB): The Pediatric Oncology Group ‘better risk’ study. Proc Am Soc Clin Oncol 11:365.

    Google Scholar 

  181. Evans AE, D’Angio GJ, Koop CE. 1984. The role of multimodal therapy in patients with local and regional neuroblastoma. J Pediatr Surg 19:77–80.

    PubMed  CAS  Google Scholar 

  182. Evans AE, Brand W, de Lorimier A, et al. 1984. Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazolecarboxamide. A report from the Children’s Cancer Study Group. Am J Clin Oncol 7:3–7.

    PubMed  CAS  Google Scholar 

  183. West DC, Shamberger RC, Macklis RM, et al. 1993. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol 11:84–90.

    PubMed  CAS  Google Scholar 

  184. Castleberry RP, Kun LE, Shuster JJ, et al. 1991. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 9:789–795.

    PubMed  CAS  Google Scholar 

  185. Bowman LC, Hancock ML, Santana VM, et al. 1991. Impact of intensified therapy on clinical outcome in infants ad children with neuroblastoma: the St. Jude Children’s Research Hospital experience, 1962 to 1988. J Clin Oncol 9:1599–1608.

    PubMed  CAS  Google Scholar 

  186. Philip T, Zucker JM, Bernard JL, et al. 1991. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 9:1037–1044.

    PubMed  CAS  Google Scholar 

  187. Cheung NK, Heller G. 1991. Chemotherapy dose intensity conrrelates strongly with re-sponse, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050–1058.

    PubMed  CAS  Google Scholar 

  188. Bernard JL, Philip T, Zucker JM, et al. 1987. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen? J Clin Oncol 5:1952–1959.

    PubMed  CAS  Google Scholar 

  189. Campbell IA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. 1993. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 11:623–629.

    PubMed  CAS  Google Scholar 

  190. Kushner BH, LaQuaglia MP, Bonilla MA, et al. 1994. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607–2613.

    PubMed  CAS  Google Scholar 

  191. Haase GM, O’Leary MC, Ramsay NKC, et al. 1991. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 26:1119–1124.

    PubMed  CAS  Google Scholar 

  192. Stram DO, Matthay KK, O’Leary M, Reynolds CP, Seeger RC. 1994. Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Prog Clin Biol Res 385:287–291.

    PubMed  CAS  Google Scholar 

  193. Seeger RC, Villablanca JG, Matthay KK, et al. 1991. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 366:527–533.

    PubMed  CAS  Google Scholar 

  194. Pole JG, Casper J, Elfenbein G, et al. 1991. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:152–158.

    PubMed  CAS  Google Scholar 

  195. Kushner BH, O’Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M, Cheung NK. 1991. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9:274–279.

    PubMed  CAS  Google Scholar 

  196. Dini G, Lanino E, Garaventa A, et al. 1991. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol 9:962–969.

    PubMed  CAS  Google Scholar 

  197. Seeger RC, Matthay KK, Villablanca JG, et al. 1991. Intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT) for high risk neuroblastoma. Proc Am Soc Clin Oncol 10:310.

    Google Scholar 

  198. Dini G, Lanino E, Garaventa A, et al. 1991. Unpurged ABMT for neuroblastoma: AIEOPBMT experience. Bone Marrow Transplant 7 (Suppl. 2):92.

    PubMed  Google Scholar 

  199. Zucker JM, Philip T, Bernard JL, et al. 1991. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE3 study in 40 patients. Bone Marrow Transplant 7 (Suppl. 2):91.

    PubMed  Google Scholar 

  200. Hartmann O, Benhamou E, Beaujean F, et al. 1987. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 5:1205–1211.

    PubMed  CAS  Google Scholar 

  201. August CS, Serota FT, Koch PA, et al. 1984. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 2:609–616.

    PubMed  CAS  Google Scholar 

  202. Kushner BH, Gulati SC, Kwon JH, O’Reilly RJ, Exelby PR, Cheung NK. 1991. High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer 68:242–247.

    PubMed  CAS  Google Scholar 

  203. McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H. 1995. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. J Clin Oncol 13:2789–2795.

    PubMed  CAS  Google Scholar 

  204. Matthay KK, Atkinson JB, Stram DO, Sclch M, Reynolds CP, Seeger RC. 1993. Patterns of relatpse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 11:2226–2233.

    PubMed  CAS  Google Scholar 

  205. Pole JG. 1991. Autologous marrow transplantation in pediatric tumors. In Gale RP, Champlin RE (eds.). New Strategies in BMT. New York: Wiley Liss, pp. 413–422.

    Google Scholar 

  206. Di Caro A, Bostrom B, Moss TJ, et al. 1994. Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. Am J Pediatr Hematol Oncol 16:200–206.

    PubMed  Google Scholar 

  207. Kletzel M, Longino R, Danner K, Olszewski M, Moss T. 1994. Peripheral Blood stem cell rescue in children with advanced stage IV neuroblastoma. Prog Clin Biol Res 389:513–519.

    PubMed  CAS  Google Scholar 

  208. Shuster JJ, Cantor AB, McWilliams N, et al. 1991. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 9:1045–1049.

    PubMed  CAS  Google Scholar 

  209. Pinkerton CR, Philip T, Biron P, et al. 1987. High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: a phase II study. Med Pediatr Oncol 15:236–240.

    PubMed  CAS  Google Scholar 

  210. Reynolds CP, Seeger RC, Vo DD, Black AT, Wells J, Ugelstad J. 1986. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 46:5882–5886.

    PubMed  CAS  Google Scholar 

  211. Moss TJ, Cairo M, Santana VM, Weinthal J, Hurvitz C, Bostrom B. 1994. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 83:3085–3089.

    PubMed  CAS  Google Scholar 

  212. Brenner MK, Rill DR, Moen RC, et al. 1994. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci 716:204–214.

    PubMed  CAS  Google Scholar 

  213. Moss TJ, Ross AA. 1992. The risk of tumor cell contamination in peripheral blood stem cell collections, J Hematother 1:225–232.

    PubMed  CAS  Google Scholar 

  214. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. 1991. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219–226.

    PubMed  CAS  Google Scholar 

  215. Moss TJ, Sanders DG, Lasky LC, Bostrom B. 1990. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 76:1879–1883.

    PubMed  CAS  Google Scholar 

  216. Wiseman GA, Kvols LK. 1995. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 25:272–278.

    PubMed  CAS  Google Scholar 

  217. Gaze MN, Wheldon TE. 1996. Radiolabelled mIBG in the treatment of neuroblastoma. Eur J Cancer 32A:93–96.

    PubMed  CAS  Google Scholar 

  218. Garaventa A, Guerra P, Arrighini A, et al. 1991. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer 67:922–928.

    PubMed  CAS  Google Scholar 

  219. Voule PA, Hoefnagel CA, de Kraker J, Valdes Olmos R, Bakker DJ, van de Kleij AJ. 1991. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 366:439–445.

    Google Scholar 

  220. Lashford LS, Lewis IJ, Fielding SL, et al. 1992. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Chidren’s Cancer Study Group investigation. J Clin Oncol 10:1889–1896.

    PubMed  CAS  Google Scholar 

  221. Matthay KK, Huberty JP, Hattner RS, et al. 1991. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 35:244–247.

    PubMed  CAS  Google Scholar 

  222. Mastrangelo R, Tornesello A, Riccardi R, et al. 1995. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 31A:606–611.

    PubMed  CAS  Google Scholar 

  223. Pritchard J, Kiely E, Rogers DW, et al. 1987. Long-term survival after advanced neuroblastoma. N Engl J Med 317:1026–1027.

    PubMed  CAS  Google Scholar 

  224. Hoefnagel CA, de Kraker J, Valdes Olmos RA, Voute PA. 1994. 1311-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 15:712–717.

    PubMed  Google Scholar 

  225. de Kraker J, Hoefnagel CA, Caron H, et al. 1995. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 31A:600–602.

    PubMed  Google Scholar 

  226. Voule PA, van der Kleij AJ, de Kraker J, Hoefnagel CA, Tiel-van Buul MM, Van Gennip H. 1995. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 31A:596–600.

    Google Scholar 

  227. Mueller-Klieser W, Vaupel P, Manz R. 1983. Tumour oxygenation under normobaric and hyperbaric conditions. Br J Radiol 56:559–564.

    PubMed  CAS  Google Scholar 

  228. Sostman HD, Rockwell S, Sylvia AL, et al. 1991. Evaluaton of BA1112 rhabdomyosarcoma oxygenation with microelectrodes, optical spectrophotometry, radiosensitivity, and magnetic resonance spectroscopy. Magn Reson Med 20:253–267.

    PubMed  CAS  Google Scholar 

  229. Fujimura E. 1974. Experimental studies on radiation effects under high pressure oxygen. Osaka Daigaku Shigaku Zasshi 19:100–108.

    PubMed  CAS  Google Scholar 

  230. Yeh SD, Larson SM, Burch L, et al. 1991. Radioimmunodetection of neuroblastoma with iodine-131–3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 32:769–776.

    PubMed  CAS  Google Scholar 

  231. Moyes JS, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ. 1989. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with enuroblastoma: correlation with tumor histopathology. J Nucl Med 30:474–480.

    PubMed  CAS  Google Scholar 

  232. Srkalovic G, Cai RZ, Schally AV. 1990. Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab 70:661–669.

    PubMed  CAS  Google Scholar 

  233. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. 1987. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098–1104.

    PubMed  CAS  Google Scholar 

  234. Cheung NK, Lazarus H, Miraldi FD, et al. 1987. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430–1440.

    PubMed  CAS  Google Scholar 

  235. Murray JL, Cunningham JE, Brewer H, et al. 1994. Phase I trial of murine monoclonal antibody l4G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184–193.

    PubMed  CAS  Google Scholar 

  236. Reisfeld RA, Mueller BM, Handgretinger R, Yu AL, Gillies SD. 1994. Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. Prog Brain Res 101:201–212.

    PubMed  CAS  Google Scholar 

  237. Cheung NK, Kushner BH, Yeh SL Larson SM. 1994. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. Prog Clin Biol Res 385:319–328.

    PubMed  CAS  Google Scholar 

  238. Hank JA, Surfus J, Gan J, et al. 1994. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15:29–37.

    CAS  Google Scholar 

  239. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. 1985. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 135:242–246.

    PubMed  CAS  Google Scholar 

  240. Michon J, Negrier S, Coze C, et al. 1994. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-East of France Group Study. Prog Clin Biol Res 385:293–300.

    PubMed  CAS  Google Scholar 

  241. Negrier S, Michon J, Floret D, et al. 1991. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 9:1363–1370.

    PubMed  CAS  Google Scholar 

  242. Favrot MC, Floret D, Negrier S, et al. 1989. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4:499–503.

    PubMed  CAS  Google Scholar 

  243. Bauer M, Reaman GH, Hank JA, et al. 1995. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin’s lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75:2959–2965.

    PubMed  CAS  Google Scholar 

  244. Evans A, Main E, Zier K, et al. 1989. The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma. A preliminary report. Cancer 64:1383–1387.

    PubMed  CAS  Google Scholar 

  245. Villablanca JG, Khan AA, Avramis VI, et al. 1995. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13:894–901.

    PubMed  CAS  Google Scholar 

  246. Finklestein JZ, Krailo MD, Lenarsky C, et al. 1992. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pedialr Oncol 20:307–311.

    Google Scholar 

  247. Adamson PC. 1994. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. Leukemia 8 (Suppl 3):22–25.

    Google Scholar 

Download references

Authors
  1. Susan L. Cohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dafna Meitar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morris Kletzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois, USA

    David O. Walterhouse M.D.  & Susan L. Cohn M.D.  & 

  2. Department of Pediatrics, Children’s Memorial Hospital, Chicago, Illinois, USA

    David O. Walterhouse M.D.  & Susan L. Cohn M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cohn, S.L., Meitar, D., Kletzel, M. (1997). Neuroblastoma: solving a biologic puzzle. In: Walterhouse, D.O., Cohn, S.L. (eds) Diagnostic and Therapeutic Advances in Pediatric Oncology. Cancer Treatment and Research, vol 92. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5767-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5767-8_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7643-9

  • Online ISBN: 978-1-4615-5767-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation